American Society of Hematology

Friday Scientific Workshops

Applications for the 2019 Friday Scientific Workshops have now closed.

The Friday Scientific Workshops are interactive discussions of the latest scientific developments in a particular field of hematology. The 2019 workshops will take place Friday, December 6, 2019, from 1:00 p.m. to 6:00 p.m. in Orlando, FL.

All registered ASH annual meeting attendees are welcome to attend these workshops. There is no additional fee to attend.

Detailed program information from the 2018 Friday Scientific Workshops can be found below.

For questions about the 2019 Friday Scientific Workshop, please contact ASH Scientific Affairs Manager Alice Kuaban akuaban@hematology.org.

Friday Scientific Workshop on Hematology and Aging: Scientific Advances From Sickle Cell Disease to Malignant Hematology

Workshop Schedule

Opening Remarks

Co-Chairs:

Rebecca L. Olin, MD
University of California, San Francisco
San Francisco, CA

Co-Chairs:

Rebecca L. Olin, MD
University of California, San Francisco
San Francisco, CA

Sickle Cell Disease in the Aging Individual

Moderator:

Brandon Blue, MD
Moffitt Cancer Center
Tampa, FL

Speakers:

Swee Lay Thein, DSc,FRCP,FRCPath,MBBS,MRCPath,MRCP
National Heart, Lung & Blood Institute
Bethesda, MD
Sickle Cell Disease in the Aging Patient – Where Do We Go from Here?

John J. Strouse, MD, PhD
Duke University School of Medicine
Durham, NC
Geriatric Assessment in Sickle Cell Disease

Andrew I. Schamess, MD
The Ohio State University
Columbus, OH
The Older Sickle Cell Patient: It Takes a Village

Panel Discussion/Questions

Acute Myeloid Leukemia

Moderator:

Heidi D. Klepin, MD
Wake Forest University School of Medicine
Winston Salem, NC

Speakers:

Karin L. Gaensler, MD
University of California San Francisco
San Francisco, CA
TriLeukeVax: A Next Generation Autologous Acute Myeloid Leukemia Vaccine for Transplant Ineligible Older Patients

Timothy S. Pardee, MD, PhD
Wake Forest Baptist Health
Winston Salem, NC
Leveraging the Biological Hallmarks of Aging to Improve Outcomes in Elderly Patients with Acute Myeloid Leukemia

Guido Marcucci, MD
City of Hope
Duarte, CA
Aging, Clonal Hematopoiesis and Therapy-related Myeloid Neoplasms: Personalizing the Risk of Chemotherapy Treatments

Martine Extermann, MD
Moffitt Cancer Center
Tampa, FL
Acute Myeloid Leukemia in Older Adults – Surveillance, Epidemiology and End Results-Medicare Modelling of Prognosis

Panel Discussion/Questions

Stem Cell Biology, Transplantation & Aging

Moderator:

Andrew S. Artz, MD
University of Chicago Hospital
Chicago, IL

Speakers:

Wendy Pang, MD, PhD
Stanford University
Stanford, CA
Strategy for Improving Hematopoietic Stem Cell (HSC) Transplantation in Elderly Myelodysplastic Syndrome (MDS) Patients: Anti-CD117 Antibody to Deplete normal and MDS HSCs

Siddhartha Jaiswal, MD, PhD
Stanford University
Los Altos, CA
Clonal Hematopoiesis in Human Aging and Disease

Thuy T. Koll, MD
University of Nebraska Medical Center
Omaha, NE
An Expanded Framework to Measure Cognitive Function in Older Adults Undergoing Hematopoietic Cell Transplantation

Panel Discussion/Questions

Multiple Myeloma

Moderator:

Tanya Wildes, MD
Washington University
Saint Louis, MO

Speakers:

Arun P. Wiita, MD, PhD
University of California San Francisco
San Francisco, CA
Enhancing Immunotherapy Efficacy for Aging Myeloma Patients Ineligible for Transplant

Sonja Zweegman, MD, PhD
Vrije Universiteit Amsterdam
Amsterdam, Netherlands
Multiple Myeloma in the Elderly; Beyond Myeloma Biology - Has the Time Come to Implement Biological Markers of Aging?

Ashley E. Rosko, MD
The Ohio State University
Columbus, OH
Gauging Fitness with Biologic Correlates in Multiple Myeloma

Matthew T. Drake, MD, PhD
Mayo Clinic
Rochester, MN
Osteoporosis in Older Adults with Monoclonal Gammopathies

Panel Discussion/Questions

Closing Remarks

Co-Chairs:

Rebecca L. Olin, MD
University of California, San Francisco
San Francisco, CA

Co-Chairs:

Rebecca L. Olin, MD
University of California, San Francisco
San Francisco, CA

back to top

Friday Scientific Workshop on Inherited Hematopoietic Malignancies

Workshop Schedule

Opening Remarks

Co-Chairs:

Lucy A. Godley, MD,PhD
University of Chicago Medical Center
Chicago, IL

Co-Chairs:

Lucy A. Godley, MD,PhD
University of Chicago Medical Center
Chicago, IL

Establishing a Hematopoietic Predisposition Clinic

Moderators:

Lucy A. Godley, MD,PhD
The University of Chicago
Chicago, IL

Kim E. Nichols, MD
St Jude Children's Research Hospital
Memphis, TN

Speakers:

Marshall S. Horwitz, MD, PhD
University of Washington
Seattle, WA
Establishing a Hematological Malignancy Clinic at the Seattle Cancer Care Alliance

Panagiotis Baliakas, MD, PhD
Uppsala University
Uppsala, Sweden
Dealing with Hematological Malignancies with Germline Predisposition in Routine Clinical Practice

Emily Quinn, MS
Keck Graduate Institute
Claremont, CA
Incorporating Genetic Counselors into the Hematopoietic Predisposition Malignancies Clinic

Michelle Boals, MSN
St. Jude Children's Research Hospital
Memphis, TN
Incorporating Nurse Practitioners into the Hematopoietic Malignancies Predisposition Clinic

Identifying Known and Novel Germline Variants

Moderators:

Marcin W. Wlodarski, MD, PhD
St. Jude Children's Research Hospital
Memphis, TN

Kaan Boztug, MD
Ludwig Boltzmann Institute for Rare and Undiagnosed Diseases
Vienna, Austria

Speakers:

Michelle L. Churchman, PhD
St. Jude Children's Research Hospital
Memphis, TN
Acute Lymphoblastic Leukemia (ALL) Predisposition: Germline Genetic IKZF1 Variation and Predisposition to Childhood ALL

Paul P. Liu, MD
National Institutes of Health
Bethesda, MD
Establishing an FPDMM Program in the NIH Clinical Center

Abhishek A. Mangaonkar, MD
Mayo Clinic
Rochester, MN
Recognition of Inherited Bone Marrow Failure Syndromes through a Genomics Approach for Patients with Unexplained Cytopenias: Experience and Clinical Utility of a Precision Genomics Clinic

Rakesh K. Goyal, MBBS,MD,MRCP
Children's Mercy Hospital
Kansas City, MO
Outcomes of Hematopoietic Cell Transplantation in Patients with Germline SAMD9/SAMD9L Mutations

Pedigree Review: Discussion of Interesting Pedigrees and New Variants

Moderators:

Sharon A. Savage, MD
National Cancer Institute
Bethesda, MD

Ian Majewski, PhD
The Walter and Eliza Hall Institute of Medical Research
Melbourne, Australia

Speakers:

Anna Byrjalsen, MD
Rigshospitalet
Copenhagen East, DNK
Update from the Staging Study: A Case of Germline Bi-Allelic Mutations in DDX41- a Putative Novel Childhood Leukemia Predisposition Gene

Mathijs A. Sanders, PhD, MSc
Erasmus University Medical Center
Rotterdam, Netherlands
MBD4 in Inherited Myeloid Malignancy

Fernanda Martins Rodrigues, MSc
Washington University in St. Louis
Saint Louis, MO
Germline Variants in Multiple Myeloma

Ensi Voshtina, DO
Medical College of Wisconsin
Milwaukee, WI
Systematic Screening for Familial Leukemia Based on Somatic Genomic Profiling Results

Dan Liu
Chinese Academy of Sciences
Beijing, China
APP As a Candidate Familial Eosinophilia Predisposition Gene

Variant Evaluation Including Demonstration of ClinGen Initiative

Moderators:

Hideki Muramatsu, MD, PhD
Nagoya University Graduate School of Medicine
Nagoya, Japan

Shannon K. McWeeney, PhD
Oregon Health & Science University
Portland, OR

Speakers:

Michael C. Chicka, PhD
Prevention Genetics
Marshfield, WI
ClinGen Update

Chimene Kesserwan, MD
St. Jude Children's Hospital
Memphis, TN
ClinGen Update

Anna L. Brown, PhD,BSc
Centre For Cancer Biology, SA Pathology/IMVS
Adelaide, SA, Australia
Development of a Data Portal for Aggregation and Analysis of Genomics Data in Familial Platelet Disorder with Predisposition to Myeloid Malignancy- the RUNX1.db

Ethical Discussion Surrounding Testing

Moderators:

Inga Hofmann, MD
University of Wisconsin
Madison, WI

Sarah Bannon, MS
The University of Texas MD Anderson Cancer Center
Houston, TX

Exciting New Research Findings

Moderators:

Timothy S. Olson, MD, PhD
The Children's Hospital of Philadelphia
Philadelphia, PA

Mary Y. Armanios, MD
Johns Hopkins University
Baltimore, MD

Speakers:

Elissa M. Furutani, MD
Boston Children's Hospital
Boston, MA
Pilot Study of Metformin in Fanconi Anemia

Raffaele Renella, MD, PhD
University Hospital of Lausanne
Lausanne, Switzerland
Seizing Opportunities in the Molecular and Cellular Dissection of Unique Phenotypes in Pediatric Myelodysplastic Syndromes

Adam J. de Smith, PhD
University of Southern California
Los Angeles, CA
Germline GAB2 Mutations in Childhood Acute Lymphoblastic Leukemia

Ulla Wartiovaara-Kautto, MD, PhD
University of Helsinki
Helsinki, Finland
Joint Pediatric and Adult Rare Hematological Disorders Outpatient Clinic in Helsinki University Hospital: Experiences and Scientific Discoveries

Closing Remarks

Co-Chairs:

Lucy A. Godley, MD,PhD
The University of Chicago
Chicago, IL

Co-Chairs:

Lucy A. Godley, MD,PhD
The University of Chicago
Chicago, IL

back to top

Friday Scientific Workshop on Integrative Epidemiology: Translating Epidemiology and Basic Science to Maximize Clinical Impact

Workshop Schedule

Opening Remarks

Co-Chairs:

James M. Foran, MD
Mayo Clinic Florida
Jacksonville, FL

Co-Chairs:

James M. Foran, MD
Mayo Clinic Florida
Jacksonville, FL

New Findings from Population Studies of B-Cell Lymphoproliferative Disorders

Moderators:

James R. Cerhan, MD, PhD
Mayo Clinic
Rochester, MN

Wendy Cozen, DO,MPH
University of Southern California
Los Angeles, CA

Speakers:

Sophia S. Wang, PhD
City of Hope
Duarte, CA
Human Leukocyte Antigen Diversity As a Risk Factor for Lymphoma

Maher K. Gandhi, PhD
University of Queensland Diamantina Institute
Brisbane, QLD, Australia
Immunologic Predictors of Outcome in Non-Hodgkin and Hodgkin Lymphoma: Are Population-Based Studies Possible?

Juan Manuel Mejia-Arangure, PhD
Instituto Mexicano del Seguro Social
Mexico, DF, MEX
Molecular Epidemiology of Pediatric Leukemias in Mexico

Karin E. Smedby
Karolinska University Hospital
Stockholm, Sweden
Population-Based Studies of Diffuse Large B-Cell Lymphoma Outcomes in Sweden with a Focus on the Elderly Patients

Irene M. Ghobrial, MD
Dana-Farber Cancer Institute
Boston, MA
Stand up to Cancer: Citizen Science to Discover Predictors of Monoclonal Gammopathy of Undetermined Significance (MGUS) and MGUS Progression

Alyssa I. Clay-Gilmour, Ph.D
Mayo Clinic
Rochester, MN
Extending Genome Wide Association Studies of Multiple Myeloma to Elicit Clues to Etiology

Elizabeth E. Brown, PhD, MPH
University of Alabama at Birmingham
Birmingham, AL
DNA Methylation Patterns in Monoclonal Gammopathy of Undetermined Significance and Myeloma Predicts Progression

Wendy Cozen, DO,MPH
University of Southern California
Los Angeles, CA
EBV Viral Load, EBV Tumor Status and Germline Genotype in U.S. and French Adolescent/ Young Adult Hodgkin Lymphoma Patients

Future Directions & Collaborations

Epidemiology of Myeloid Malignancy: Clonal Hematopoiesis as an Epidemiologic Risk Factor, Population-Based Studies and Health Outcomes

Moderators:

James M. Foran, MD
Mayo Clinic Florida
Jacksonville, FL

Lindsay M. Morton, PhD
National Cancer Institute, NIH, DHHS
Bethesda, MD

Speakers:

Catherine Metayer, MD, PhD
University of California Berkeley
Berkeley, CA
Update on Epidemiology of Pediatric Acute Myeloid Leukemia

Kelly Bolton, MD, PhD
Memorial Sloan Kettering Cancer Center
New York, NY
Clonal Hematopoiesis As a Disease Risk Factor Following Chemotherapy and Radiotherapy

Koichi Takahashi, MD
The University of Texas M.D. Anderson Cancer Center
Houston, TX
Clonal Hematopoiesis As an Acute Myeloid Leukemia Risk Factor and Extending to Its Impact on Minimal Residual Disease and Outcome after Therapy

Lindsay M. Morton, PhD
National Cancer Institute, NIH, DHHS
Bethesda, MD
The Epidemiology of Therapy-Related Myeloid Malignancy in the Modern Treatment Era

Nandita Khera, MD
Mayo Clinic
Phoenix, AZ
Impact of Disparities and Access to Allogeneic Transplantation for Acute Myeloid Leukemia

Lara E. Sucheston-Campbell, PhD,MS
Cancer Prevention & Control
Columbus, OH
Molecular Epidemiology of Acute Myeloid Leukemia - GEMM Consortium

James M. Foran, MD
Mayo Clinic Florida
Jacksonville, FL
Clinical Risk Factors and Association with Cytogenetic & Molecular Phenotype and Outcome in Acute Myeloid Leukemia

Alexandra Smith, PhD
University of York
York, United Kingdom
Real World Epidemiology of Myeloid Malignancy – Incidence and Outcomes

Future Directions & Collaborations

Closing Remarks

Co-Chairs:

James M. Foran, MD
Mayo Clinic Florida
Jacksonville, FL

Co-Chairs:

James M. Foran, MD
Mayo Clinic Florida
Jacksonville, FL

back to top

Friday Scientific Workshop on Myeloid Development

Workshop Schedule

Opening Remarks

Co-Chairs:

Ross L. Levine, MD
Memorial Sloan Kettering Cancer Center
New York, NY

Co-Chairs:

Ross L. Levine, MD
Memorial Sloan Kettering Cancer Center
New York, NY

Stem Cells

Moderator:

Patricia Ernst, PhD
University of Colorado Denver
Aurora, CO

Speakers:

Linda Resar, MD
Johns Hopkins University SOM
Baltimore, MD
High Mobility Group A1 Chromatin Remodeling Protein Deficiency Results in Global Defects in Stem Cell Function and Premature Aging Phenotypes

Guy Sauvageau, MD
The Leucegene Project at the Institute for Research in Immunology and Cancer (IRIC)
Montréal, QC, Canada
UM171 in 420 Seconds

Hanna Mikkola, MD, PhD
University of California, Los Angeles
Los Angeles, CA
Human Hematopoietic Stem Cell Self-Renewal and Engraftment Are Enhanced By the Transcriptional Regulator MLLT3

Yan Liu, PhD
ndiana University School of Medicine
Indianapolis, IN
Mutant p53 Promotes Hematopoietic Stem and Progenitor Cell Expansion through Interacting with Epigenetic Modulator EZH2

Signaling and Developmental Hematopoiesis

Moderator:

Claudia Lengerke, MD
University Hospital Basel
Basel, Switzerland

Speakers:

Eirini Trompouki, PhD
Max Planck Institute of Immunobiology and Epigenetics
Freiburg, Germany
Role of RIG-I-like Receptors in Developmental Hematopoiesis

Trista E North, PhD
Boston Children's Hospital
Boston, MA
YAP Regulates Hematopoietic Stem Cell Formation in Response to the Biophysical Forces of Blood Flow

Shannon McKinney-Freeman, PhD
St. Jude Children's Research Hospital
Memphis, TN
The Global Clonal Complexity of the Murine Blood System Declines throughout Life and after Serial Transplantation

Simon Mendez-Ferrer, PhD
Centro Nacional De Investigaciones Cardiovasculares
Cambridge, ENG, Spain
The Bone Marrow Microenvironment Promotes Myeloid Differentiation During Premature or Physiological Aging

New Investigators

Moderator:

Nancy E. Speck, PhD
University of Pennsylvania
Philadelphia, PA

Speakers:

Zuzana Tothova, MD, PhD
Dana-Farber Cancer Institute
Cambridge, MA
STAG2 Mutations Alter Cohesin Ring Function and Provide Therapeutic Vulnerabilities in Acute Myeloid Leukemia

Anna E. Beaudin, PhD
University of California Merced
Merced, CA
The Lymphoid Associated IL7R Regulates Tissue Resident Macrophage Development

Christopher M. Sturgeon, PhD
Washington University School of Medicine
St.Louis, MO
Ontogeny As a Critical Determinant of Natural Killer Cell Potential and Function

Chun-Wei Chen, PhD
City of Hope
Duarte, CA
High-Density CRISPR Scan Identifies Functional Regions of DOT1L That Mediate Therapeutic Response in MLL-r Leukemia

Katie Kathrein, PhD
University of South Carolina
Columbia, SC
Ing4 Regulates Hematopoiesis through Suppression of NF-Kb

NIH Updates

Speakers:

Cindy N. Roy, PhD
National Institute of Diabetes, Digestive, and Kidney Disease
Bethesda, MD
NIDDK Presentation

Pankaj Qasba, PhD
National Institutes of Health
Bethesda, MD
NHLBI Presentation

Transcription Factors/Epigenetics

Moderator:

Ulrich G. Steidl, MD, PhD
Albert Einstein College of Medicine
Bronx, NY

Speakers:

Mark Dawson, PhD, MBBS
Peter MacCallum Cancer Centre
Melbourne, AUS
Non-Genomic Mechanisms of Therapeutic Resistance

Shannon M. Buckley, PhD
University of Nebraska Medical Center
Omaha, NE
Loss of E3 Ligase, FBXO9 Leads to Acceleration and Progression of Acute Myeloid Leukemia

Daisuke Nakada, PhD
Baylor College of Medicine
Houston, TX
PRDM16 Changes the Fate of Megakaryocytic Cells to Acute Myeloid Leukemia Initiating Cells

Margaret H. Baron, MD
Mount Sinai School of Medicine
New York, NY
Stimulation of the Proliferation of Mouse and Human Definitive Erythroid Progenitors By Activation of the Vitamin D Receptor Transcription Factor

Myeloid Malignancies

Moderator:

Benjamin L. Ebert, MD,PhD
Harvard Medical School
Boston, MA

Speakers:

Warren S. Pear, MD,PhD
University of Pennsylvania
Philadelphia, PA
Oncogenic Notch Promotes Long-Range Regulatory Interactions within Hyperconnected 3D Cliques

Maria E. Figueroa, MD
University of Miami
Miami, FL
Aging Human Hematopoietic Stem Cells Manifest Profound Epigenetic Reprogramming of Enhancers Linked to Cancer Pathways

Thomas Mercher, PhD
Institut Gustave Roussy
Villejuif, France
Ontogeny-Dependent Susceptibility to Fusion Oncogenes Controls Pediatric Myeloid Leukemia

Jeffrey W. Tyner, PhD
Oregon Health & Science University
Portland, OR
Leveraging of the Beat Acute Myeloid Leukemia 1.0 Dataset to Understand Drug Sensitivity and Resistance

Closing Remarks

Co-Chairs:

Ross L. Levine, MD
Memorial Sloan Kettering Cancer Center
New York, NY

Co-Chairs:

Ross L. Levine, MD
Memorial Sloan Kettering Cancer Center
New York, NY

back to top

Friday Scientific Workshop on Tumor Immune Interactions in Lymphoid Malignancies

Workshop Schedule

Opening Remarks

Co-Chairs:

Stephen M. Ansell, MD, PhD
Mayo Clinic
Rochester, MN

Co-Chairs:

Stephen M. Ansell, MD, PhD
Mayo Clinic
Rochester, MN

Novel Targets and Proteomics

Moderators:

Stephen M. Ansell, MD, PhD
Mayo Clinic
Rochester, MN

Ronald Levy, MD
Stanford University
Stanford, CA

Speakers:

Ash A. Alizadeh, MD,PhD
Stanford University
Stanford, CA
Immune Cell Deconvolution By Learning from Single Cells

Kojo S. J. Elenitoba-Johnson, MD
University of Pennsylvania
Philadelphia, PA
Using Functional Proteogenomics to Identify Biomarkers and Therapeutic Targets in Lymphoma

Panel Discussion

Engaging Natural Killer Cells and Macrophages

Moderators:

Stephen M. Ansell, MD, PhD
Mayo Clinic
Rochester, MN

Ronald Levy, MD
Stanford University
Stanford, CA

Speakers:

Ahmed Sawas, MD
Columbia University Irving Medical Center
New York, NY
Engaging Natural Killer Cells in T-Cell Lymphoma

Bob Uger, PhD
Trillium Therapeutics Inc.
Mississauga, ON, Canada
CD47 Directed Therapy in B-Cell Malignancies

Panel Discussion

“Bulking up” Chimeric Antigen Receptor (CAR) T-cells

Moderators:

Stephen M. Ansell, MD, PhD
Mayo Clinic
Rochester, MN

Ronald Levy, MD
Stanford University
Stanford, CA

Speakers:

Marco Ruella, MD
University of Pennsylvania
Philadelphia, PA
Overcoming the Immunosuppressive Microenvironment in Chimeric Antigen Receptor T-Cell Therapy for Lymphoma

Becker Hewes, MD
Torque Therapeutics
WINCHESTER, MA
Cell-Based Delivery Systems in Lymphoid Malignancies

Panel Discussion

Closing Remarks

Co-Chairs:

Stephen M. Ansell, MD, PhD
Mayo Clinic
Rochester, MN

Co-Chairs:

Stephen M. Ansell, MD, PhD
Mayo Clinic
Rochester, MN

back to top